Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication

Toshihiro Kawaguchi(Kurume University), Takuji Torimura(Omuta hospital), Reiichiro Kuwahara(Kurume University), Tatsuya Ide(Kurume University), Tomoya Sano, Teruko Arinaga‐Hino(Kurume University), Shirachi Miki, Naofumi Ono(Saga Medical School Hospital), Keisuke Amano(Kurume University)
Molecular and Clinical Oncology
August 23, 2021
10.3892/mco.2021.2377
Cited by 15

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
|Liver International|2020|410